Bilaal.Raja
Company record

KRRO  Korro Bio, Inc.

Trailing twelve months to 2026-06-30, as filed 2026-08-06 and not restated since.
Healthcare

Scale

Market cap
$142m
Revenue TTM
$2m
Net income TTM
$-107m
Free cash flow
$-68m
Composite score
—
Sector rank
#2942

Valuation

P / E
—
EV / EBITDA
—
EV / sales
11.3
FCF yield
-48.09%
Yield vs 10-yr
-80.37pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 5.28% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-4,477.1%
EBITDA margin
-4,515.1%
ROE
-103.3%
ROIC
—
Revenue growth
—

Insider activity, last 90 days

Net open-market
$-5.20m
Buyers
1
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Delays or difficulties in patient enrollment or difficulties retaining trial participants, including as a result of the availability of existing or other investigational treatments, can result in increased costs, longer development times or termination of a clinical trial. In connection with the growth and advancement of our pipeline, we expect that we will need to increase the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs, and as any development candidates near later stage clinical trials and potential commercialization by us, and sales and marketing. …Korro Bio, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →